Show simple item record

dc.contributor.authorPersani, Lucaen
dc.contributor.authorBrabant, Georgen
dc.contributor.authorDattani, Mehulen
dc.contributor.authorBonomi, Marcoen
dc.contributor.authorFeldt-Rasmussen, Ullaen
dc.contributor.authorFliers, Ericen
dc.contributor.authorGruters, Annetteen
dc.contributor.authorMaiter, Dominiqueen
dc.contributor.authorSchoenmakers, Nadiaen
dc.contributor.authorvan Trotsenburg, AS Paulen
dc.date.accessioned2018-12-01T00:30:32Z
dc.date.available2018-12-01T00:30:32Z
dc.date.issued2018-10en
dc.identifier.issn2235-0640
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286192
dc.description.abstractCentral Hypothyroidism (CeH) is a rare form of hypothyroidism characterized by insufficient thyroid stimulation due to disturbed pituitary and/or hypothalamic functioning. Due to its origin and the whole clinical context, CeH represents a challenging condition in clinical practice as it is characterized by suboptimal accuracy of clinical and biochemical parameters for diagnosis and management. Since no expert consensus or guidance for this condition is currently available, a task force of experts received the commitment from the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. The task force started to work in February 2017 and after 1-year work, a preliminary presentation and live discussion during the 2017 ETA meeting, and several revision rounds has prepared a list of recommendations to support the diagnosis and management of patients with CeH. Due to the particular challenges of this rare condition in the different ages, the target users of this guidance are pediatric and adult Endocrinologists. Experts agreed on the need to recognize and treat overt CeH at all ages, whereas treatment of milder forms may be dispensable in the elderly (>75 years). Despite the lack of randomized controlled clinical trials, the experts provide 34 recommendations supported by variable levels of strength that should improve the quality of life of the affected patients and reduce the metabolic and hormonal consequences of inadequate management.
dc.description.sponsorshipThis is a guidelines article so funding sources are not acknowledged. However, my personal grant is from the Wellcome Trust
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherKarger
dc.title2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism.en
dc.typeArticle
prism.endingPage237
prism.issueIdentifier5en
prism.publicationDate2018en
prism.publicationNameEuropean thyroid journalen
prism.startingPage225
prism.volume7en
dc.identifier.doi10.17863/CAM.33504
dcterms.dateAccepted2018-08-22en
rioxxterms.versionofrecord10.1159/000491388en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-10en
dc.contributor.orcidPersani, Luca [0000-0003-2068-9581]
dc.contributor.orcidBonomi, Marco [0000-0001-5454-6074]
dc.contributor.orcidSchoenmakers, Nadia [0000-0002-0847-2884]
dc.contributor.orcidvan Trotsenburg, AS Paul [0000-0002-9677-7441]
dc.identifier.eissn2235-0802
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idWellcome Trust (100574/Z/12/Z)
pubs.funder-project-idWellcome Trust (100585/Z/12/Z)
pubs.funder-project-idMRC (MC_UU_12012/5)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record